Page 170 - 磁共振成像2024年7期电子刊

磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7 综 述｜｜Reviews

参考文献[References] 11C-methionine positron emission tomography image improves the
diagnostic accuracy of cerebral glioma grading[J]. Jpn J Radiol, 2017,
[1] ZHAO Z, ZHANG K N, WANG Q W, et al. Chinese glioma genome 35(10): 613-621. DOI: 10.1007/s11604-017-0675-2.
atlas (CGGA): a comprehensive resource with functional genomic data [20] NINATTI G, SOLLINI M, BONO B, et al. Preoperative[11C]
from Chinese glioma patients[J]. Genomics Proteomics Bioinformatics, methionine PET to personalize treatment decisions in patients with
2021, 19(1): 1-12. DOI: 10.1016/j.gpb.2020.10.005. lower-grade gliomas[J]. Neuro Oncol, 2022, 24(9): 1546-1556. DOI:
[2] VAN DEN BENT M J, GEURTS M, FRENCH P J, et al. Primary brain 10.1093/neuonc/noac040.
tumours in adults[J]. Lancet, 2023, 402(10412): 1564-1579. DOI: [21] ROESSLER K, GATTERBAUER B, BECHERER A, et al. Surgical
10.1016/S0140-6736(23)01054-1. target selection in cerebral glioma surgery: linking methionine (MET)
[3] HERVEY-JUMPER S L, ZHANG Y L, PHILLIPS J J, et al. Interactive PET image fusion and neuronavigation[J]. Minim Invasive Neurosurg,
effects of molecular, therapeutic, and patient factors on outcome of 2007, 50(5): 273-280. DOI: 10.1055/s-2007-991143.
diffuse low-grade glioma[J]. J Clin Oncol, 2023, 41(11): 2029-2042. [22] VON ROHR K, UNTERRAINER M, HOLZGREVE A, et al. Can
DOI: 10.1200/JCO.21.02929. radiomics provide additional information in[18F]FET-negative
[4] KARSCHNIA P, SMITS M, REIFENBERGER G, et al. A framework gliomas?[J/OL]. Cancers, 2022, 14(19): 4860 [2024-05-23]. https://
for standardised tissue sampling and processing during resection of pubmed.ncbi.nlm.nih.gov/36230783/. DOI: 10.3390/cancers14194860.
diffuse intracranial glioma: joint recommendations from four RANO [23] PICCARDO A, ALBERT N L, BORGWARDT L, et al. Joint EANM/
groups[J/OL]. Lancet Oncol, 2023, 24(11): e438-e450 [2024-05-23]. SIOPE/RAPNO practice guidelines/SNMMI procedure standards for
https://pubmed.ncbi.nlm.nih.gov/37922934/. DOI: 10.1016/S1470-2045 imaging of paediatric gliomas using PET with radiolabelled amino
(23)00453-9. acids and[ F]FDG: version 1.0[J]. Eur J Nucl Med Mol Imaging,
18
[5] GALLDIKS N, LOHMANN P, FINK G R, et al. Amino acid PET in 2022, 49(11): 3852-3869. DOI: 10.1007/s00259-022-05817-6.
neurooncology[J]. J Nucl Med, 2023, 64(5): 693-700. DOI: 10.2967/ [24] IDEGUCHI M, NISHIZAKI T, IKEDA N, et al. A surgical strategy
jnumed.122.264859. using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET
[6] EISAZADEH R, SHAHBAZI-AKBARI M, MIRSHAHVALAD S A, and MRI for glioma with no or minimum contrast enhancement[J]. J
et al. Application of artificial intelligence in oncologic molecular Neurooncol, 2018, 138(3): 537-548. DOI: 10.1007/s11060-018-2821-9.
18
PET-imaging: a narrative review on beyond[ F]F-FDG tracers part II. [25] INOUE A, OHNISHI T, KOHNO S, et al. Met-PET uptake index for total
[ F]F-FLT, [ F]F-FET, [ C]C-MET and other less-commonly used tumor resection: identification of C-methionine uptake index as a goal for
18
11
18
11
radiotracers[J]. Semin Nucl Med, 2024, 54(2): 293-301. DOI: 10.1053/ total tumor resection including infiltrating tumor cells in glioblastoma[J].
j.semnuclmed.2024.01.002. Neurosurg Rev, 2021, 44(1): 587-597. DOI: 10.1007/s10143-020-01258-7.
[7] ZHOU W Y, ZHOU Z R, WEN J B, et al. A nomogram modeling [26] MILLER S, LI P, SCHIPPER M, et al. Metabolic tumor volume
11 C-MET PET/CT and clinical features in glioma helps predict IDH response assessment using (11)C-methionine positron emission tomography
mutation[J/OL]. Front Oncol, 2020, 10: 1200 [2024-05-23]. https:// identifies glioblastoma tumor subregions that predict progression better
pubmed.ncbi.nlm.nih.gov/32850348/. DOI: 10.3389/fonc.2020.01200. than baseline or anatomic magnetic resonance imaging alone[J]. Adv
18
[8] SONG S S, WANG L M, YANG H W, et al. Static F-FET PET and Radiat Oncol, 2019, 5(1): 53-61. DOI: 10.1016/j.adro.2019.08.004.
DSC-PWI based on hybrid PET/MR for the prediction of gliomas [27] ALTIERI R, CERTO F, PACELLA D, et al. Metabolic delineation of
defined by IDH and 1p/19q status[J]. Eur Radiol, 2021, 31(6): IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor
4087-4096. DOI: 10.1007/s00330-020-07470-9. extent of resection[J]. J Neurooncol, 2023, 162(2): 417-423. DOI:
[9] CHEN Q, WANG K, REN X H, et al. Individualized discrimination of 10.1007/s11060-023-04305-7.
tumor progression from treatment-related changes in different types of [28] YAMAMOTO S, OKITA Y, ARITA H, et al. Qualitative MR features
11
adult-type diffuse gliomas using[ C]methionine PET[J]. J Neurooncol, to identify non-enhancing tumors within glioblastoma's T2-FLAIR
2023, 165(3): 547-559. DOI: 10.1007/s11060-023-04529-7. hyperintense lesions[J]. J Neurooncol, 2023, 165(2): 251-259. DOI:
[10] ZHOU W Y, WEN J B, HUANG Q, et al. Development and validation 10.1007/s11060-023-04454-9.
of clinical-radiomics analysis for preoperative prediction of IDH [29] GROSU A L, ASTNER S T, RIEDEL E, et al. An interindividual
mutation status and WHO grade in diffuse gliomas: a consecutive comparison of O- (2- [18F]fluoroethyl) -L-tyrosine (FET) - and
L-[methyl-11C]methionine cohort study with two PET scanners[J]. Eur L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas
J Nucl Med Mol Imaging, 2024, 51(5): 1423-1435. DOI: 10.1007/s00259- and metastases[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1049-1058.
023-06562-0. DOI: 10.1016/j.ijrobp.2010.07.002.
[11] KAISER L, QUACH S, ZOUNEK A J, et al. Enhancing predictability [30] KAISER L, HOLZGREVE A, QUACH S, et al. Differential spatial
of IDH mutation status in glioma patients at initial diagnosis: a distribution of TSPO or amino acid PET signal and MRI contrast
18
comparative analysis of radiomics from MRI, [ F]FET PET, and TSPO enhancement in gliomas[J/OL]. Cancers, 2021, 14(1): 53 [2024-05-23].
PET[J]. Eur J Nucl Med Mol Imaging, 2024, 51(8): 2371-2381. DOI: https://pubmed.ncbi.nlm.nih.gov/35008218/. DOI: 10.3390/cancers14010053.
10.1007/s00259-024-06654-5. [31] ALLARD B, DISSAUX B, BOURHIS D, et al. Hotspot on 18F-FET
[12] NAKAYAMA N, YAMADA T, YANO H, et al. Prediction of nuclide PET/CT to predict aggressive tumor areas for radiotherapy dose
accumulation spread based on the volume of enhancing magnetic escalation guiding in high-grade glioma[J/OL]. Cancers, 2022, 15(1):
resonance imaging lesion in glioblastoma patients[J]. J Neurosurg Sci, 98 [2024-05-23]. https://pubmed. ncbi. nlm. nih. gov/36612093/. DOI:
2024, 68(2): 164-173. DOI: 10.23736/S0390-5616.21.05353-4. 10.3390/cancers15010098.
[13] LOHMEIER J, RADBRUCH H, BRENNER W, et al. Detection of [32] LATRECHE A, DISSAUX G, QUERELLOU S, et al. Correlation
recurrent high-grade glioma using microstructure characteristics of between rCBV delineation similarity and overall survival in a
distinct metabolic compartments in a multimodal and integrative prospective cohort of high-grade gliomas patients: the hidden value of
18F-FET PET/fast-DKI approach[J]. Eur Radiol, 2024, 34(4): 2487-2499. multimodal MRI? [J/OL]. Biomedicines, 2024, 12(4): 789 [2024-05-23].
DOI: 10.1007/s00330-023-10141-0. https://pubmed.ncbi.nlm.nih.gov/38672146/. DOI: 10.3390/biomedicines
[14] PANHOLZER J, MALSINER-WALLI G, GRÜN B, et al. 12040789.
Multiparametric analysis combining DSC-MR perfusion and[18F] [33] STEGMAYR C, STOFFELS G, FILß C, et al. Current trends in the use
FET-PET is superior to aSingle parameter approach for differentiation of O- (2- [ F]fluoroethyl) -L-tyrosine ([18F]FET) in neurooncology[J/OL].
18
of progressive glioma from radiation necrosis[J]. Clin Neuroradiol, Nucl Med Biol, 2021, 92: 78-84 [2024-05-23]. https://pubmed. ncbi.
2024, 34(2): 351-360. DOI: 10.1007/s00062-023-01372-1. nlm.nih.gov/32113820/. DOI: 10.1016/j.nucmedbio.2020.02.006.
[15] FRAIOLI F, SHANKAR A, HYARE H, et al. The use of [34] SONG S S, CHENG Y, MA J, et al. Simultaneous FET-PET and
multiparametric 18F-fluoro-L-3, 4-dihydroxy-phenylalanine PET/MRI contrast-enhanced MRI based on hybrid PET/MR improves delineation
in post-therapy assessment of patients with gliomas[J]. Nucl Med of tumor spatial biodistribution in gliomas: a biopsy validation study[J]. Eur
Commun, 2020, 41(6): 517-525. DOI: 10.1097/MNM.0000000000001184. J Nucl Med Mol Imaging, 2020, 47(6): 1458-1467. DOI: 10.1007/s00259-
[16] HARAT M, RAKOWSKA J, HARAT M, et al. Combining amino acid 019-04656-2.
PET and MRI imaging increases accuracy to define malignant areas in [35] HARAT M, MIECHOWICZ I, RAKOWSKA J, et al. A biopsy-controlled
adult glioma[J/OL]. Nat Commun, 2023, 14(1): 4572 [2024-05-23]. prospective study of contrast-enhancing diffuse glioma infiltration based on
https://pubmed.ncbi.nlm.nih.gov/37516762/. DOI: 10.1038/s41467-023- FET-PET and FLAIR[J/OL]. Cancers, 2024, 16(7): 1265 [2024-05-23].
39731-8. https://pubmed.ncbi.nlm.nih.gov/38610944/. DOI: 10.3390/cancers16071265.
[17] VERBURG N, KOOPMAN T, YAQUB M M, et al. Improved [36] LI X R, CHENG Y, HAN X, et al. Exploring the association of glioma
18
detection of diffuse glioma infiltration with imaging combinations: a tumor residuals from incongruent[ F]FET PET/MR imaging with
diagnostic accuracy study[J]. Neuro Oncol, 2020, 22(3): 412-422. DOI: tumor proliferation using a multiparametric MRI radiomics nomogram[J].
10.1093/neuonc/noz180. Eur J Nucl Med Mol Imaging, 2024, 51(3): 779-796. DOI: 10.1007/
[18] TIETZE A, BOLDSEN J K, MOURIDSEN K, et al. Spatial s00259-023-06468-x.
distribution of malignant tissue in gliomas: correlations of [37] PONISIO M R, MCCONATHY J E, DAHIYA S M, et al. Dynamic
11C-L-methionine positron emission tomography and perfusion- and 18 F-FDOPA-PET/MRI for the preoperative evaluation of gliomas:
diffusion-weighted magnetic resonance imaging[J]. Acta Radiol, 2015, correlation with stereotactic histopathology[J]. Neurooncol Pract, 2020,
56(9): 1135-1144. DOI: 10.1177/0284185114550020. 7(6): 656-667. DOI: 10.1093/nop/npaa044.
[19] WU R L, WATANABE Y, ARISAWA A, et al. Whole-tumor histogram [38] TATEKAWA H, UETANI H, HAGIWARA A, et al. Worse prognosis
analysis of the cerebral blood volume map: tumor volume defined by for IDH wild-type diffuse gliomas with larger residual biological tumor
https://www.chinesemri.com ·163 ·